Get started
Author

Shinichi Yoshigoe

Observed names: S Yoshigoe, S Yoshigoe -, S., Yoshigoe, Yoshigoe, Shinichi
ORCID: 0000-0003-2704-054X
Observed ORCID: 0000-0003-2704-054X
OpenAlex ID: A5040526542
Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn’s Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn’s Disease (iCREST-CD)
2023 · Takayuki Yamamoto, Hiroshi Nakase, et al. · Journal of Crohn s and Colitis · 48
PDF
Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD)
2022 · Katsuyoshi Matsuoka, Toshimitsu Fujii, et al. · Journal of Gastroenterology · 34
Correction: Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD)
2023 · Katsuyoshi Matsuoka, Toshimitsu Fujii, et al. · Journal of Gastroenterology · 2
PDF
Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan
2022 · Shiro Nakamura, Teita Asano, et al. · Inflammatory Intestinal Diseases · 2
P775 Disease activity and treatment patterns of newly diagnosed adult patients with Crohn's disease in Japan: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD)
2023 · S Shinzaki, K Matsuoka, et al. · Journal of Crohn s and Colitis · 1
Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn’s disease: an interim analysis of an inception cohort registry study (iCREST-CD)
2026 · Shinichiro Shinzaki, Katsuyoshi Matsuoka, et al. · Journal of Crohn s and Colitis
Using Pre-Study Patient Interviews to Refine Electronic Patient-Reported Outcomes in Clinical Research of Ustekinumab Induction for Ulcerative Colitis (SIRIUS Study)
2026 · Katsumasa Nagano, Shun Emoto, et al. · Advances in Therapy
PDF
Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active Ulcerative colitis: post-hoc analysis of QUASAR
2026 · A Dignaß, F Hirai, et al. · Zeitschrift für Gastroenterologie
Mo1518 SYMPTOMATIC IMPROVEMENT WITH INTRAVENOUS GUSELKUMAB INDUCTION THERAPY IS OBSERVED EARLY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST-HOC ANALYSIS OF QUASAR
2026 · Axel Dignass, Fumihito Hirai, et al. · Gastrointestinal Endoscopy
Mo1518 SYMPTOMATIC IMPROVEMENT WITH INTRAVENOUS GUSELKUMAB INDUCTION THERAPY IS OBSERVED EARLY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST-HOC ANALYSIS OF QUASAR
2026 · Axel Dignass, Fumihito Hirai, et al. · Gastroenterology
OP10 Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active Ulcerative Colitis: post-hoc analysis of QUASAR
2026 · A Dignass, F Hirai, et al. · Journal of Crohn s and Colitis
P0326 Disease Behaviour Progression and Associated Factors in Crohn’s Disease Patients: the Nationwide Inception Cohort Study of Crohn’s Disease (iCREST-CD)
2026 · K Matsuoka, T Fujii, et al. · Journal of Crohn s and Colitis
PDF
Assessment of healthcare resource utilization and direct medical cost in relation to treatment length of oral corticosteroids in biologic-initiated patients with ulcerative colitis: a Japanese claims database study
2025 · Celine Miyazaki, Tomoyuki Inoue, et al. · Journal of Medical Economics
Tu1115 CLINICAL CHARACTERISTICS AND IMPACT ON DAILY LIFE IN JAPANESE CROHN'S DISEASE PATIENTS: A MULTICENTER REGISTRY STUDY.
2024 · Yohei Mikami, Katsuyoshi Matsuoka, et al. · Gastroenterology
P1189 Clinical features and surgical necessity rate of fistulising perianal disease in newly diagnosed patients with Crohn's disease: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD)
2024 · N Takatsu, T Yamamoto, et al. · Journal of Crohn s and Colitis
PDF
P466 Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
2022 · S Nakamura, T Asano, et al. · Journal of Crohn s and Colitis
PDF
Supplementary Material for: Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-week Results from Post-marketing Surveillance in Japan
2022 · S., Nakamura, T., Asano, et al. · Figshare
P172 Clinical characteristics of newly diagnosed adult patients with Crohn’s disease in Japan: Interim analysis of Inception cohort registry study of patients with Crohn’s disease (iCREST-CD)
2021 · K Matsuoka, T Fujii, et al. · Journal of Crohn s and Colitis
PDF
Works count: 19
Citation count: 87
H-index: 2
I10-index: 2
Year
Topic
Type